Trial Profile
A Phase 1/2 Study of ARQ 092 (Miransertib) in Subjects With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Miransertib (Primary)
- Indications Growth disorders; Proteus syndrome
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms MOSAIC
- Sponsors ArQule; Merck Sharp & Dohme
- 10 May 2022 Status changed from active, no longer recruiting to discontinued as this study did not meet the efficacy objective.
- 10 Feb 2022 Planned End Date changed from 14 Apr 2022 to 14 Jun 2022.
- 10 Feb 2022 Planned primary completion date changed from 14 Apr 2022 to 14 Jun 2022.